Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma Q3 net loss widens to $30.1 million on $20.0 million license payment

Mixed Impact 4 of 5 earnings Written later

Nuvectis Pharma reported third-quarter 2026 results, with a net loss of $30.1 million compared with $7.5 million a year earlier. The loss includes a one-time $20.0 million upfront payment for the NXP100 and NXP200 license agreement. The company reported $140.7 million in cash at September 30, 2026, and says this funds operations into the second half of 2029.

Key points

  • Net loss was $30.1 million for the quarter ended September 30, 2026, versus $7.5 million a year earlier, including a $20.0 million upfront license payment.
  • Basic and diluted net loss per share was $1.02, compared with $0.44 in the third quarter of 2025.
  • Cash and cash equivalents were $140.7 million at September 30, 2026, up from $31.6 million at December 31, 2025, after a $115.0 million follow-on offering in July.
  • Ciprocopan (NXP100) was approved in China in July 2026 for PNH; the company expects an update on the U.S. FDA path by year-end.

The filing

CompanyNuvectis Pharma, Inc. (NVCT)
Form8-K, current report
Filed with the SECNov 4, 2026, 7:06 AM ET
Accession number0001104659-26-122360

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.